Treatment of Biofilm Communities: An Update on New Tools from the Nanosized World

The translation from bench-to-bed occurred mainly for cancer treatment. Since 1995, when Doxil®, a liposomal-encapsulated form of doxorubicin to reduce its cardiotoxicity [10], earned the approval from the Federal Drug Administration (FDA), many other nano-drugs reached the clinics. According to the traditional classification, the second class of nanoparticles is the group of organic NPs, where organic molecules are part of the composition of the nanoparticles and exert an inherent antibiofilm action. [...]nanoproducts included in the class in which inorganic and organic components are combined can fit either in type 1 or type 2 NDDSs, based on the number of different components that the nanosystem carries. The intense academic research in the field of antimicrobial nanotechnologies should be carefully designed towards a future possible clinical application. [...]deep characterization of the nanosystem needs to be provided early in the development of the product, pointing out to the necessity of a strict and strong collaboration between many different expertises (chemistry, biology, pharmacological, engineering, and clinical) during the development of the nanodrug.